Publications by authors named "Paul Ankah"
Article Synopsis
- COVID-19 significantly impacts patients with sickle cell disease (SCD), yet limited data exists on how different hemoglobin (Hb) genotypes affect infection outcomes.
- Researchers analyzed hospitalized COVID-19 cases in SCD patients from the National Inpatient Sample, focusing on various treatment and mortality outcomes across different Hb genotypes (HbSS, HbSC, and HbSβ).
- The study found that while HbSS was the most common genotype, there were no significant differences in in-hospital outcomes among the genotypes, indicating a need for further research to understand this finding.
Introduction: There is a paucity of data on the outcomes of coronavirus disease 2019 (COVID-19) in patients with sickle cell disease (SCD) in the United States. We examined the outcomes of patients with COVID-19 and SCD.
Methods: We utilized the National Inpatient Sample (NIS) to identify the data of patients diagnosed with COVID-19 and SCD in 2020 using the International Classification of Disease, Tenth Revision codes.